Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus (Q36390892)

13 August 2017

1 reference

title

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus (English)

1 reference

13 August 2017

1 reference

1 reference

Brian K Irons

1

1 reference

13 August 2017

Ronald Shane Greene

2

1 reference

13 August 2017

Timothy A Mazzolini

3

1 reference

13 August 2017

Krystal L Edwards

4

1 reference

13 August 2017

Rebecca B Sleeper

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

26

1 reference

13 August 2017

2

1 reference

13 August 2017

168-181

1 reference

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

13 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Economic costs of diabetes in the US in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

The platelet in diabetes: focus on prevention of ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Lipids and lipoproteins in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Atherogenic lipoprotein particles in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Associations of low density lipoprotein particle composition with atherogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

The relationship between hyperinsulinemia, hypertension and progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Adiponectin and future coronary heart disease events among men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Inflammatory markers and the risk of coronary heart disease in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

C-reactive protein and incident cardiovascular events among men with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Obesity as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Association of simple anthropometric measures of obesity with visceral fat and the metabolic syndrome in male Caucasian and Indo-Asian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Free fatty acids and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Matrix metalloproteinases and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Preclinical atherosclerosis and inflammation in 61-year-old men with newly diagnosed diabetes and established diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation. Intravascular ultrasound studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Thiazolidinedione-associated congestive heart failure and pulmonary edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Metformin and thiazolidinedione use in Medicare patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Adiposity as Compared with Physical Activity in Predicting Mortality among Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.168

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.7326/0003-4819-141-6-200409210-00007

Identifiers

DOI

10.1592/PHCO.26.2.168

1 reference

13 August 2017

1 reference